Opponents file lawsuit targeting medication abortions
Nov 18, 2022, 4:40 PM | Updated: 5:07 pm
AUSTIN, Texas (AP) — Abortion opponents who helped challenge Roe v. Wade filed a lawsuit Friday that takes aim at medication abortions, asking a federal judge in Texas to undo decades-old approval of the drugs that have become the preferred method of ending pregnancy in the U.S.
Even before the Supreme Court struck down the constitutional right to an abortion earlier this year, the use of abortion pills had been increasing in the U.S. and demand is expected to grow as more states seek abortion limits.
The lawsuit was filed by the Alliance for Defending Freedom, which was also involved in the Mississippi case that led to Roe v. Wade being overturned. The lawsuit argues the U.S. Food and Drug Administration erred in approving the drugs mifepristone and misoprostol and overstepped its authority in doing so.
Reached for comment, the FDA said it does not comment on pending or ongoing litigation.
The lawsuit was filed in federal court in Amarillo, Texas. The state banned abortion after the Roe decision and is among the states where GOP lawmakers have banned mail delivery of the pills.
Medication abortions have increased in popularity since regulators started allowing them and now account for roughly 40% of U.S. abortions. The medication can cost as little as $110 to get by mail, compared with at least $300 for a surgical abortion. Research has shown the pills are safe.
However, people seeking abortion pills often must navigate differing state laws, including bans on delivery of the drugs and on telemedicine consultations to discuss the medication with a health care provider. And until Democrat Joe Biden became president, U.S. government policy banned mail delivery nationwide.
Abortion medication is approved for use up to the 10th week of pregnancy. The pills may be taken in a doctor’s office or clinic, where patients sometimes have an ultrasound or lab tests beforehand.
Copyright © The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.
